These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28255377)

  • 1. Pathophysiological changes of inflammatory syndrome in multiple sclerosis after instituting therapeutic plasmapheresis.
    Vlaic S; Poalelungi V; Bălăeţ M; Purcărea VL; Bălăeţ C; Coculescu BI
    J Med Life; 2017; 10(1):50-53. PubMed ID: 28255377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmapheresis decreases neuroelectric blocking activity in multiple sclerosis.
    Stefoski D; Schauf CL; McLeod BC; Haywood CP; Davis FA
    Neurology; 1982 Aug; 32(8):904-7. PubMed ID: 7201588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study].
    Meca-Lallana JE; Rodríguez-Hilario H; Martínez-Vidal S; Saura-Luján I; Carretón-Ballester A; Escribano-Soriano JB; Martín-Fernández J; Genovés-Aleixandre A; Mateo-Bosch E; Fernández-Barreiro A
    Rev Neurol; 2003 Nov 16-30; 37(10):917-26. PubMed ID: 14634919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A closer look at plasmapheresis in multiple sclerosis: the cons.
    Tindall R
    Neurology; 1988 Jul; 38(7 Suppl 2):53-6. PubMed ID: 3290716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasmapheresis in neurology -- personal experience].
    Załeska B; Domzał T; Korsak J
    Neurol Neurochir Pol; 1994; 28(2):167-74. PubMed ID: 8047226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of therapeutic plasmapheresis in demyelinating neurologic disorders.
    Tindall RS; Rollins JA
    South Med J; 1986 Aug; 79(8):991-7. PubMed ID: 3016910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal of valproic acid by plasmapheresis in a patient treated for multiple sclerosis.
    Bastiaans DE; van Uden IW; Ruiterkamp RA; de Jong BA
    Ther Drug Monit; 2013 Feb; 35(1):1-3. PubMed ID: 23222689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.
    Magaña SM; Pittock SJ; Lennon VA; Keegan BM; Weinshenker BG; Lucchinetti CF
    Arch Neurol; 2009 Aug; 66(8):964-6. PubMed ID: 19667216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmapheresis in multiple sclerosis: preliminary study.
    Weiner HL; Dawson DM
    Neurology; 1980 Oct; 30(10):1029-33. PubMed ID: 7191492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros.
    Khatri BO
    Neurology; 1988 Jul; 38(7 Suppl 2):50-2. PubMed ID: 3290715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone.
    Tindall RS; Walker JE; Ehle AL; Near L; Rollins J; Becker D
    Neurology; 1982 Jul; 32(7):739-43. PubMed ID: 7201110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis.
    Medenica RD; Mukerjee S; Huschart T; Corbitt W
    J Clin Apher; 1994; 9(4):216-21. PubMed ID: 7759466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis.
    Hauser SL; Fosburg M; Kevy S; Weiner HL
    Prog Clin Biol Res; 1982; 106():239-54. PubMed ID: 6184727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmapheresis combined with interferon: an effective therapy for multiple sclerosis.
    Medenica RD; Mukerjee S; Alonso K; Lazovic G; Huschart T
    J Clin Apher; 1994; 9(4):222-7. PubMed ID: 7538999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic apheresis in multiple sclerosis].
    Nomura K
    Nihon Rinsho; 2003 Aug; 61(8):1388-95. PubMed ID: 12962028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful treatment with additional plasmapheresis for the exacerbation of acute neurological symptoms in a girl with multiple sclerosis].
    Mogami Y; Yamada K; Toribe Y; Yanagihara K; Mano T; Suzuki Y
    No To Hattatsu; 2011 Jan; 43(1):36-40. PubMed ID: 21400930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Childhood multiple sclerosis treated with plasmapheresis.
    Takahashi I; Sawaishi Y; Takeda O; Enoki M; Takada G
    Pediatr Neurol; 1997 Jul; 17(1):83-7. PubMed ID: 9308985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmapheresis in acute multiple sclerosis: rationale and results.
    Dau PC
    J Clin Apher; 1991; 6(4):200-4. PubMed ID: 1816240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.